Good morning, everyone, and how are you today? We are just fine, thank you, especially since we are poised to enjoy an extended holiday break, during which time we hope to hang with our short people and observe important rituals. We hope that those of you on this side of the pond are doing the same. Have a wonderful time and, for everyone else, well, you will survive. To help speed things along, meanwhile, here are some tidbits. We hope you have a smashing few days and look forward to seeing you soon …

The Food and Drug Administration approved the first two-drug regimen to treat HIV, Reuters writes. The treatment, called Juluca, is a fixed-dose tablet combining two previously approved drugs, ViiV Healthcare’s dolutegravir and Johnson & Johnson’s rilpivirine. ViiV is majority-owned by GlaxoSmithKline (GSK), and the approval puts Glaxo ahead of Gilead Sciences (GILD) in the race to market with two-drug combinations for HIV treatments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy